Creating a vaccine to generate antibodies against HIV-1.
Official title: Induction of bnAbs against HIV-1 gp41.
Funded at Neovaxsyn, INC. · NIH-10695185 · Data updated 2026-11-12
This study is testing a new type of vaccine designed to help your body make powerful antibodies that can fight off many strains of HIV-1, with the hope of reducing infections and making a big difference in the battle against AIDS.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neovaxsyn, INC. NIH-funded |
| Lab location | 1 site (Ames, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $300,000 |
| NIH project number | 5R43MH133248-02 |
| Project ID | NIH-10695185 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals at high risk of HIV-1 infection or those living with HIV who are seeking preventive options.
✕Less likely to help
Patients who are already on effective antiretroviral therapy and have well-controlled HIV-1 infections may not benefit directly from this research.
What this research studies
This research aims to develop a novel vaccine strategy called Antibody-Stabilized, Epitope Presentation (ASEP) to induce broadly neutralizing antibodies (bnAbs) against HIV-1. The focus is on eliciting antibodies similar to 10E8, which can neutralize a vast majority of HIV-1 strains. By using precisely defined immune complexes as immunogens, the research seeks to create a protective vaccine that could significantly reduce HIV infections. If successful, this approach could lead to a breakthrough in the fight against AIDS.
Why it matters
Potential benefit: If successful, this research could lead to the development of an effective vaccine that protects against HIV-1 infections.
How similar studies have gone: Other research has shown promise in developing vaccines that induce bnAbs, but this specific ASEP strategy is a novel approach.
Where this research is happening
-
Neovaxsyn, INC.
Ames, United States Active
Researchers
- Principal investigator: Hu, Yong — Neovaxsyn, INC.
- Study coordinator: Hu, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.